Mast cells and metabolic syndrome

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 1, 2012, Pages 14-20

  Zhang, Jie ^a   Shi, Guo Ping ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Diabetes; Hypertension dyslipidemia; Mast cell; Metabolic syndrome; Obesity

Indexed keywords

CATHEPSIN G; CATHEPSIN L; CATHEPSIN S; CD11B ANTIGEN; CD31 ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHYMASE; COLLAGEN; CROMOGLYCATE DISODIUM; CYSTEINE PROTEINASE; GAMMA INTERFERON; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; KETOTIFEN FUMARATE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEDOCROMIL; RANTES; RENIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ADIPOCYTE; ANGIOGENESIS; ANKYLOSING SPONDYLITIS; BODY MASS; BRAIN DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SIZE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; EFFECTOR CELL; ENZYME BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEART MUSCLE FIBROSIS; HEART VENTRICLE FIBROSIS; HELPER CELL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAST CELL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, WHITE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; HUMANS; HYPERTENSION; INFLAMMATION; INFLAMMATION MEDIATORS; MAST CELLS; METABOLIC DISEASES; OBESITY;

ANIMALIA;

EID: 82955180309     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.12.012     Document Type: Review

References (98)

1. von Recklinghausen F. Ueber eiter- und bindegewebskörperchen. Virchows Arch 1863, 28:157-197.
2. Waldeyer W. Ueber Bindegewebeszellen. Arch Mikrosk Anat 1875, 11:176-194.
3. Ehrlich P. Beitr kenntniss anilinfarbungen verwendung mikroskopischen technik 1877, 13:263-277.
4. Kitamura Y., Shimada M., Hatanaka K., Miyano Y. Development of mast cells from grafted bone marrow cells in irradiated mice. Nature 1977, 268:442-443.
5. Nabel G., Galli S.J., Dvorak A.M., Dvorak H.F., Cantor H. Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells. Nature 1981, 291:332-334.
6. Metcalfe D.D., Baram D., Mekori Y.A. Mast cells. Physiol Rev 1997, 77:1033-1079.
7. Kawakami T., Galli S.J. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002, 2:773-786.
8. Galli S.J., Zsebo K.M., Geissler E.N. The kit ligand, stem cell factor. Adv Immunol 1994, 55:1-96.
9. Kitamura Y. Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol 1989, 7:59-76.
10. Dvorak A.M. Basophil and mast cell degranulation and recovery. Blood Cell Biochemistry 1991, vol. 4. Plenum, New York, NY.
11. Dvorak A.M. Basophils and mast cells: piecemeal degranulation in situ and ex vivo: a possible mechanism for cytokine-induced function in disease. Immunol Ser 1992, 57:169-271.
12. Caughey G.H. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 2007, 217:141-154.
13. Krishnaswamy G., Ajitawi O., Chi D.S. The human mast cell: an overview. Meth Mol Biol 2006, 315:13-34.
14. Ventre J., Doebber T., Wu M., MacNaul K., Stevens K., Pasparakis M., Kollias G., Moller D.E. Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes 1997, 46:1526-1531.
15. Pejler G., Abrink M., Ringvall M., Wernersson S. Mast cell proteases. Adv Immunol 2007, 95:167-255.
16. Okumura S., Kashiwakura J., Tomita H., Matsumoto K., Nakajima T., Saito H., Okayama Y. Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FcepsilonRI. Blood 2003, 102:2547-2554.
17. Metzger H. The receptor with high affinity for IgE. Immunol Rev 1992, 125:37-48.
18. Marshall J.S. Mast-cell responses to pathogens. Nat Rev Immunol 2004, 4:787-799.
19. Lu L.F., Lind E.F., Gondek D.C., Bennett K.A., Gleeson M.W., Pino-Lagos K., Scott Z.A., Coyle A.J., Reed J.L., Van Snick J., Strom T.B., Zheng X.X., Noelle R.J. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006, 442:997-1002.
20. Grimbaldeston M.A., Nakae S., Kalesnikoff J., Tsai M., Galli S.J. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 2007, 8:1095-1104.
21. Kitamura Y., Go S., Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978, 52:447-452.
22. Lyon M.F., Glenister P.H. A new allele sash (Wsh) at the W-locus and a spontaneous recessive lethal in mice. Genet Res 1982, 39:315-322.
23. Berrozpe G., Timokhina I., Yukl S., Tajima Y., Ono M., Zelenetz A.D., Besmer P. The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154kb upstream of Kit. Blood 1999, 94:2658-2666.
24. Duttlinger R., Manova K., Chu T.Y., Gyssler C., Zelenetz A.D., Bachvarova R.F., Besmer P. W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. Development 1993, 118:705-717.
25. Wolters P.J., Mallen-St Clair J., Lewis C.C., Villalta S.A., Baluk P., Erle D.J., Caughey G.H. Tissue-selective mast cell reconstitution and differential lung gene expression in mast cell-deficient Kit(W-sh)/Kit(W-sh) sash mice. Clin Exp Allergy 2005, 35:82-88.
26. Sun J., Sukhova G.K., Wolters P.J., Yang M., Kitamoto S., Libby P., MacFarlane L.A., Mallen-St Clair J., Shi G.P. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007, 13:719-724.
27. Liu J., Divoux A., Sun J., Zhang J., Clement K., Glickman J.N., Sukhova G.K., Wolters P.J., Du J., Gorgun C.Z., Doria A., Libby P., Blumberg R.S., Kahn B.B., Hotamisligil G.S., Shi G.P. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009, 15:940-945.
28. Ebmeyer J., Ebmeyer U., Pak K., Sudhoff H., Broide D., Ryan A.F., Wasserman S. Reconstitution of the mast cell population in W/Wv mice. Otol Neurotol 2010, 31:42-47.
29. Galli S.J., Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008, 49:7-19.
30. Dvorak A.M. Mast-cell degranulation in human hearts. N Engl J Med 1986, 315:969-970.
31. Bennett J.L., Blanchet M.R., Zhao L., Zbytnuik L., Antignano F., Gold M., Kubes P., McNagny K.M. Bone marrow-derived mast cells accumulate in the central nervous system during inflammation but are dispensable for experimental autoimmune encephalomyelitis pathogenesis. J Immunol 2009, 182:5507-5514.
32. Fukuda K., Ohbayashi M., Morohoshi K., Zhang L., Liu F.T., Ono S.J. Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis. J Allergy Clin Immunol 2009, 124:827-833. e822.
33. Kneilling M., Hultner L., Pichler B.J., Mailhammer R., Morawietz L., Solomon S., Eichner M., Sabatino J., Biedermann T., Krenn V., Weber W.A., Illges H., Haubner R., Rocken M. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 2007, 56:1806-1816.
34. Kaartinen M., Penttila A., Kovanen P.T. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha. Circulation 1996, 94:2787-2792.
35. Hara M., Ono K., Hwang M.W., Iwasaki A., Okada M., Nakatani K., Sasayama S., Matsumori A. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 2002, 195:375-381.
36. Ihara M., Urata H., Kinoshita A., Suzumiya J., Sasaguri M., Kikuchi M., Ideishi M., Arakawa K. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999, 33:1399-1405.
37. Tsuruda T., Kato J., Hatakeyama K., Yamashita A., Nakamura K., Imamura T., Kitamura K., Onitsuka T., Asada Y., Eto T. Adrenomedullin in mast cells of abdominal aortic aneurysm. Cardiovasc Res 2006, 70:158-164.
38. Sun J., Sukhova G.K., Yang M., Wolters P.J., MacFarlane L.A., Libby P., Sun C., Zhang Y., Liu J., Ennis T.L., Knispel R., Xiong W., Thompson R.W., Baxter B.T., Shi G.P. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007, 117:3359-3368.
39. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956, 4:20-34.
40. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
41. Groop L. Genetics of the metabolic syndrome. Br J Nutr 2000, 83(Suppl 1):S39-S48.
42. Zimmet P., Boyko E.J., Collier G.R., de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann NY Acad Sci 1999, 892:25-44.
43. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
44. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
45. Wu H., Ghosh S., Perrard X.D., Feng L., Garcia G.E., Perrard J.L., Sweeney J.F., Peterson L.E., Chan L., Smith C.W., Ballantyne C.M. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007, 115:1029-1038.
46. Rausch M.E., Weisberg S., Vardhana P., Tortoriello D.V. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes Lond 2008, 32:451-463.
47. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., Otsu M., Hara K., Ueki K., Sugiura S., Yoshimura K., Kadowaki T., Nagai R. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009, 15:914-920.
48. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., Lee J., Goldfine A.B., Benoist C., Shoelson S., Mathis D. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009, 15:930-939.
49. Miller R., Wen X., Dunford B., Wang X., Suzuki Y. Cytokine production of CD8+ immune T cells but not of CD4+ T cells from Toxoplasma gondii-infected mice is polarized to a type 1 response following stimulation with tachyzoite-infected macrophages. J Interferon Cytokine Res 2006, 26:787-792.
50. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., Shimizu J., Takahashi T., Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27.
51. Hosogai N., Fukuhara A., Oshima K., Miyata Y., Tanaka S., Segawa K., Furukawa S., Tochino Y., Komuro R., Matsuda M., Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007, 56:901-911.
52. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., Wang S., Fortier M., Greenberg A.S., Obin M.S. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005, 46:2347-2355.
53. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
54. Sun J., Zhang J., Lindholt J.S., Sukhova G.K., Liu J., He A., Abrink M., Pejler G., Stevens R.L., Thompson R.W., Ennis T.L., Gurish M.F., Libby P., Shi G.P. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 2009, 120:973-982.
55. Mallen-St Clair J., Shi G.P., Sutherland R.E., Chapman H.A., Caughey G.H., Wolters P.J. Cathepsins L and S are not required for activation of dipeptidyl peptidase I (cathepsin C) in mice. Biol Chem 2006, 387:1143-1146.
56. Wang B., Sun J., Kitamoto S., Yang M., Grubb A., Chapman H.A., Kalluri R., Shi G.P. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 2006, 281:6020-6029.
57. Shi G.P., Sukhova G.K., Kuzuya M., Ye Q., Du J., Zhang Y., Pan J.H., Lu M.L., Cheng X.W., Iguchi A., Perrey S., Lee A.M., Chapman H.A., Libby P. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 2003, 92:493-500.
58. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
59. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
60. Feinstein R., Kanety H., Papa M.Z., Lunenfeld B., Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993, 268:26055-26058.
61. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
62. Uysal K.T., Wiesbrock S.M., Hotamisligil G.S. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology 1998, 139:4832-4838.
63. Moller D.E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000, 11:212-217.
64. Gonzalez-Gay M.A., De Matias J.M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A., Martin J., Llorca J. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:83-86.
65. Kiortsis D.N., Mavridis A.K., Vasakos S., Nikas S.N., Drosos A.A. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005, 64:765-766.
66. Hrnciar J., Gabor D., Hrnciarova M., Okapcova J., Szentivanyi M., Kurray P. Relation between cytokines (TNF-alpha, IL-1 and 6) and homocysteine in android obesity and the phenomenon of insulin resistance syndromes. Vnitr Lék 1999, 45:11-16.
67. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998, 83:847-850.
68. Amrani A., Jafarian-Tehrani M., Mormede P., Durant S., Pleau J.M., Haour F., Dardenne M., Homo-Delarche F. Interleukin-1 effect on glycemia in the non-obese diabetic mouse at the pre-diabetic stage. J Endocrinol 1996, 148:139-148.
69. Balakumar P., Arora M.K., Ganti S.S., Reddy J., Singh M. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol Res 2009, 60:24-32.
70. Balakumar P., Reddy J., Singh M. Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy?. Mol Cell Biochem 2009, 330:187-192.
71. Kanwar Y.S., Wada J., Sun L., Xie P., Wallner E.I., Chen S., Chugh S., Danesh F.R. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med Maywood 2008, 233:4-11.
72. Jones S.E., Kelly D.J., Cox A.J., Zhang Y., Gow R.M., Gilbert R.E. Mast cell infiltration and chemokine expression in progressive renal disease. Kidney Int 2003, 64:906-913.
73. Okon K., Stachura J. Increased mast cell density in renal interstitium is correlated with relative interstitial volume, serum creatinine and urea especially in diabetic nephropathy but also in primary glomerulonephritis. Pol J Pathol 2007, 58:193-197.
74. Ruger B.M., Hasan Q., Greenhill N.S., Davis P.F., Dunbar P.R., Neale T.J. Mast cells and type VIII collagen in human diabetic nephropathy. Diabetologia 1996, 39:1215-1222.
75. Sharma K., Ziyadeh F.N. The transforming growth factor-beta system and the kidney. Semin Nephrol 1993, 13:116-128.
76. Kondo S., Kagami S., Kido H., Strutz F., Muller G.A., Kuroda Y. Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol 2001, 12:1668-1676.
77. Lindstedt K.A., Wang Y., Shiota N., Saarinen J., Hyytiainen M., Kokkonen J.O., Keski-Oja J., Kovanen P.T. Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J 2001, 15:1377-1388.
78. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
79. Nicoletti A., Heudes D., Hinglais N., Appay M.D., Philippe M., Sassy-Prigent C., Bariety J., Michel J.B. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension 1995, 26:101-111.
80. Hinglais N., Heudes D., Nicoletti A., Mandet C., Laurent M., Bariety J., Michel J.B. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest 1994, 70:286-294.
81. Nicoletti A., Heudes D., Mandet C., Hinglais N., Bariety J., Michel J.B. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res 1996, 32:1096-1107.
82. Kuwahara F., Kai H., Tokuda K., Takeya M., Takeshita A., Egashira K., Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002, 106:130-135.
83. Kuwahara F., Kai H., Tokuda K., Takeya M., Takeshita A., Egashira K., Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?. Hypertension 2004, 43:739-745.
84. Kagitani S., Ueno H., Hirade S., Takahashi T., Takata M., Inoue H. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens 2004, 22:1007-1015.
85. Olivetti G., Lagrasta C., Ricci R., Sonnenblick E.H., Capasso J.M., Anversa P. Long-term pressure-induced cardiac hypertrophy: capillary and mast cell proliferation. Am J Physiol 1989, 257:H1766-H1772.
86. Rakusan K., Turek Z. Protamine inhibits capillary formation in growing rat hearts. Circ Res 1985, 57:393-398.
87. Azizkhan R.G., Azizkhan J.C., Zetter B.R., Folkman J. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med 1980, 152:931-944.
88. Shiota N., Rysa J., Kovanen P.T., Ruskoaho H., Kokkonen J.O., Lindstedt K.A. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens 2003, 21:1935-1944.
89. Panizo A., Mindan F.J., Galindo M.F., Cenarruzabeitia E., Hernandez M., Diez J. Are mast cells involved in hypertensive heart disease?. J Hypertens 1995, 13:1201-1208.
90. Levick S.P., McLarty J.L., Murray D.B., Freeman R.M., Carver W.E., Brower G.L. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension 2009, 53:1041-1047.
91. Lee M., Lindstedt L.K., Kovanen P.T. Mast cell-mediated inhibition of reverse cholesterol transport. Arterioscler Thromb 1992, 12:1329-1335.
92. Kokkonen J.O., Kovanen P.T. Stimulation of mast cells leads to cholesterol accumulation in macrophages in vitro by a mast cell granule-mediated uptake of low density lipoprotein. Proc Natl Acad Sci USA 1987, 84:2287-2291.
93. Kokkonen J.O., Kovanen P.T. Low-density-lipoprotein binding by mast-cell granules. Demonstration of binding of apolipoprotein B to heparin proteoglycan of exocytosed granules. Biochem J 1987, 241:583-589.
94. Kokkonen J.O. Stimulation of rat peritoneal mast cells enhances uptake of low density lipoproteins by rat peritoneal macrophages in vivo. Atherosclerosis 1989, 79:213-223.
95. Ma H., Kovanen P.T. Inhibition of mast cell-dependent conversion of cultured macrophages into foam cells with antiallergic drugs. Arterioscler Thromb Vasc Biol 2000, 20:E134-E142.
96. Ma H., Kovanen P.T. IgE-dependent generation of foam cells: an immune mechanism involving degranulation of sensitized mast cells with resultant uptake of LDL by macrophages. Arterioscler Thromb Vasc Biol 1995, 15:811-819.
97. Lee M., Kovanen P.T., Tedeschi G., Oungre E., Franceschini G., Calabresi L. Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux. J Lipid Res 2003, 44:539-546.
98. Heikkila H.M., Trosien J., Metso J., Jauhiainen M., Pentikainen M.O., Kovanen P.T., Lindstedt K.A. Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation. J Cell Biochem 2010, 109:615-623.